Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors
Open Access
- 6 November 2025
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-18
Abstract
Background: Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable success in hematologic malignancies but faces significant challenges in solid tumors due to the immunosuppressive tumor microenvironment (TME). Among these, hypoxia plays a vital role, yet the molecular mediators that link hypoxia to CAR-T dysfunction remain incompletely understood. Methods: Anti-mesothelin (MSLN) CAR-T cells were cultured under normoxic (21% O 2 ) and hypoxic (1% O 2 ) conditions for six days. We assessed cell expansion, phenotypes, cytotoxicity, and metabolic features. RNA sequencing was conducted to identify key gene expression changes induced by hypoxia. Findings were further validated using anti-CD70 CAR-T cells. Results: Hypoxia reduced CAR-T proliferation, increased apoptosis, lowered memory phenotypes, raised exhaustion, and weakened cytotoxicity in short-term and long-term assays. Transcriptomic and metabolic analyses showed metabolic reprogramming with increased glycolysis and reduced oxidative phosphorylation. Among the dysregulated genes, the serine/threonine-protein kinase PIM3 emerged as a previously underexplored mediator of hypoxia-driven dysfunction. Genetic or pharmacologic inhibition of PIM3 counteracted hypoxia-induced impairment, enhancing memory phenotypes of CAR-T cells, and improving their anti-tumor activity both in vitro and in vivo. Conclusions: This work identifies PIM3 as a previously underexplored target that links hypoxia to CAR-T cell dysfunction and demonstrates that PIM3 inhibition can reverse these effects. These findings provide a mechanistic rationale for incorporating PIM3 inhibition into CAR-T cell manufacturing or engineering to improve their therapeutic potential in hypoxic solid tumors.Keywords
Funding Information
- National Natural Science Foundation of China (82373183)
- Priority Academic Program Development of Jiangsu Higher Education Institutions (2024ZB561)
- China Postdoctoral Science Foundation (2025M772868)
This publication has 62 references indexed in Scilit:
- Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunityCancer Cell, 2024
- Inosine induces stemness features in CAR-T cells and enhances potencyCancer Cell, 2024
- Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylationCell Metabolism, 2024
- PIM kinases regulate early human Th17 cell differentiationCell Reports, 2023
- Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCLMolecular Therapy-Oncolytics, 2023
- Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancerCancer Immunology, Immunotherapy, 2022
- Hypoxia, a key factor in the immune microenvironmentBiomedicine & Pharmacotherapy, 2022
- Hypoxia Is a Dominant Remodeler of the Effector T Cell Surface Proteome Relative to Activation and Regulatory T Cell SuppressionMolecular & Cellular Proteomics, 2022
- Angiogenesis as a hallmark of solid tumors - clinical perspectivesCellular Oncology, 2021
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation StatusEuropean Urology, 2016